Antiandrogen Therapy Radiosensitizes Androgen Receptor–Positive Cancers to ¹⁸F-FDG

Background: A subset (35%) of triple negative breast cancers (TNBC) express androgen receptor (AR) activity. However, clinical trials with anti-androgen drugs have shown limited efficacy with about a 19% clinical benefit rate. We investigate the therapeutic enhancement of anti-androgens as radiosensitizers in combination with ¹⁸F-fluoro-2-deoxy-D-glucose (¹⁸F-FDG) in TNBC. Methods: We screened five candidate...